{"url_path":"/sec/cldi/8-k/2026-06-23/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-029710-index.html","accession_number":"0001493152-26-029710","cik":"0001855485","ticker":"CLDI","issuer_name":"Calidi Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-029710-index.html","primary_entity_key":"0001855485","primary_entity_name":"Calidi Biotherapeutics, Inc."},"word_count":101,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nOn\nJune 23, 2026, the Company issued a press release announcing Dr. Sanders’ appointment described in this Current Report on Form\n8-K. A copy of the press release is furnished herewith as Exhibit 99.1.\n\n \n\nThe\ninformation set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18\nof the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless\nof any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing."}